Quick Answer
HERON THERAPEUTICS, INC. /DE/ reported Diluted EPS of $0.12 per share (loss) for fiscal year 2025.
HERON THERAPEUTICS, INC. /DE/ Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.12 | -33.3% |
| 2024 | -$0.09 | +88.8% |
| 2023 | -$0.80 | +52.1% |
| 2022 | -$1.67 | +25.4% |
| 2021 | -$2.24 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.10 | -233.3% | -400.0% |
| June 30, 2025 | -$0.02 | +66.7% | -300.0% |
| March 31, 2025 | $0.01 | +150.0% | +133.3% |
| September 30, 2024 | -$0.03 | +82.4% | +50.0% |
| June 30, 2024 | -$0.06 | +82.9% | -200.0% |
| March 31, 2024 | -$0.02 | +92.6% | +88.2% |
| September 30, 2023 | -$0.17 | +55.3% | +51.4% |
| June 30, 2023 | -$0.35 | +36.4% | -29.6% |
- HERON THERAPEUTICS, INC. /DE/ showed a decrease of -33.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, HERON THERAPEUTICS, INC. /DE/’s diluted eps has grown by 94.6% (from $2.24 per share (loss) to $0.12 per share (loss)).
- The most recent figure is from HERON THERAPEUTICS, INC. /DE/’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: